Does increased immunogenicity of surviving tumor cells enable cooperation between liposomal doxorubicin and IL-18?
These data demonstrate that Doxil favorably changes the immunophenotype of a large fraction of the tumor that escapes direct killing thus creating an opportunity to expand tumor killing by immunotherapy, which can be capitalized through addition of IL-18 in vivo.
LAA contraction velocities correlate poorly with multiple LA variables. Therefore, LAA flow velocities should not be used as surrogates of global LA function.